Long Noncoding RNA H19 Acts as a Competing Endogenous RNA to Mediate CTGF Expression by Sponging miR-455 in Cardiac Fibrosis.
暂无分享,去创建一个
[1] P. Shi,et al. miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1/STAT3 pathway , 2017, BMC Cardiovascular Disorders.
[2] M. C. Nunes,et al. Cardiac manifestations of parasitic diseases , 2017, Heart.
[3] J. Vandesompele,et al. Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance , 2017, Genes.
[4] S. Haemmig,et al. Targeting LncRNAs in Cardiovascular Disease: Options and Expeditions , 2017, Circulation research.
[5] Yanjie Lu,et al. MIAT Is a Pro-fibrotic Long Non-coding RNA Governing Cardiac Fibrosis in Post-infarct Myocardium , 2017, Scientific Reports.
[6] F. Zannad,et al. Myocardial fibrosis: biomedical research from bench to bedside , 2017, European journal of heart failure.
[7] Xichuang Chen,et al. MiR-22 may Suppress Fibrogenesis by Targeting TGFβR I in Cardiac Fibroblasts , 2016, Cellular Physiology and Biochemistry.
[8] Yongjun Tang,et al. The effect of H19-miR-29b interaction on bleomycin-induced mouse model of idiopathic pulmonary fibrosis. , 2016, Biochemical and biophysical research communications.
[9] Jun Li,et al. Long noncoding RNA H19 controls DUSP5/ERK1/2 axis in cardiac fibroblast proliferation and fibrosis. , 2016, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[10] Liang-Hu Qu,et al. Long non-coding RNAs link extracellular matrix gene expression to ischemic cardiomyopathy. , 2016, Cardiovascular research.
[11] Hong Xie,et al. Long non-coding RNA-H19 antagonism protects against renal fibrosis , 2016, Oncotarget.
[12] T. Geva,et al. Myocardial Fibrosis in Congenital Heart Disease. , 2016, Circulation journal : official journal of the Japanese Circulation Society.
[13] Tao Chen,et al. Long non-coding RNA H19 can predict a poor prognosis and lymph node metastasis: a meta-analysis in human cancer. , 2016, Minerva medica.
[14] Jian Wang,et al. The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy. , 2016, Cardiovascular research.
[15] Maria-Teresa Piccoli,et al. Non-coding RNAs as modulators of the cardiac fibroblast phenotype. , 2016, Journal of molecular and cellular cardiology.
[16] A. Schambach,et al. Long noncoding RNA Chast promotes cardiac remodeling , 2016, Science Translational Medicine.
[17] A. Hochberg,et al. The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision , 2015, Oncotarget.
[18] P. Galuppo,et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. , 2015, Journal of molecular and cellular cardiology.
[19] F. Weidemann,et al. Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis , 2015, European heart journal.
[20] Thomas Thum,et al. Noncoding RNAs and myocardial fibrosis , 2014, Nature Reviews Cardiology.
[21] T. Murohara,et al. Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats , 2014, Hypertension Research.
[22] W. Engström,et al. Epigenetic regulation of the Igf2/H19 gene cluster , 2014, Cell proliferation.
[23] Peilong Li,et al. The Long Noncoding RNA CHRF Regulates Cardiac Hypertrophy by Targeting miR-489 , 2014, Circulation research.
[24] B. Li,et al. miR-155 regulates high glucose-induced cardiac fibrosis via the TGF-β signaling pathway. , 2016, Molecular bioSystems.